The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Lifyorli relacorilant Orphan | Corcept Therapeutics Netherlands B.V. | Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Ovarian Epithelial | 🇪🇺 EU 2026-09-17 | Order → |
| Linhaliq | Aradigm Pharmaceuticals Limited | Bronchiectasis | 🇪🇺 EU | Order → |
| Livmarli maralixibat Orphan | FGK Representative Service GmbH | Cholestasis, Intrahepatic | 🇪🇺 EU | Order → |
| Loulla mercaptopurine Orphan | Only For Children Pharmaceuticals | Leukemia, Lymphoid | 🇪🇺 EU | Order → |
| Lumevoq lenadogene nolparvovec Orphan | GenSight Biologics S.A. | Optic Atrophy, Hereditary, Leber | 🇪🇺 EU | Order → |
| Lunivia eszopiclone | Sepracor Ltd. | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU | Order → |
| Lutholaz pegfilgrastim Biosimilar | YES Pharmaceutical Development Services GmbH | 🇪🇺 EU | Order → | |
| Luveniq voclosporin | Lux Biosciences GmbH | Uveitis | 🇪🇺 EU | Order → |
| Luxceptar Orphan | Kiadis Pharma Netherlands B.V. | Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 🇪🇺 EU | Order → |
| Lympreva dasiprotimut-t Orphan | Biovest Europe Ltd | Lymphoma, Non-Hodgkin | 🇪🇺 EU 2015-04-23 | Order → |
| Lyrokaul lerodalcibep | LIB Therapeutics B.V. | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2026-07-23 | Order → |
| Lyvdelzi (previously Seladelpar Gilead) seladelpar lysine dihydrate OrphanPRIMEConditional | Gilead Sciences Ireland Unlimited Company | Liver Cirrhosis, Biliary | 🇪🇺 EU 2024-12-12 | Order → |
| Masican masitinib Orphan | AB Science | Gastrointestinal Stromal Tumors | 🇪🇺 EU 2014-03-20 | Order → |
| Masipro masitinib Orphan | AB Science | Mastocytosis | 🇪🇺 EU 2017-09-14 | Order → |
| Masitinib AB Science masitinib Orphan | AB Science | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 2024-06-27 | Order → |
| Masiviera masitinib Orphan | AB Science | Pancreatic Neoplasms | 🇪🇺 EU 2014-05-22 | Order → |
| Megestrol Alkermes | Alkermes Pharma Ireland Ltd. | 🇪🇺 EU | Order → | |
| Memantine FGK memantine GenericConditional | FGK Representative Service GmbH | Alzheimer Disease | 🇪🇺 EU | Order → |
| Meplyffa arimoclomol Orphan | Zevra Denmark A/S | Niemann-Pick Diseases | 🇪🇺 EU 2026-07-23 | Order → |
| Mersarex | Arpida A/S | Skin Diseases, Bacterial; Soft Tissue Infections | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.